Webinars

From Pharma to CROs to real-world evidence generation platforms, compliantly accessing medical records for your project can be challenging.

As a life sciences researcher, we know that you face significant challenges when it comes to advancing precision drug discovery.

The University of Texas at Austin, Dell Medical School, the local Health Information Exchange Connxus and findhelp, a social care referral platform, collaborated to create an innovative platform that links, displays, and contextualizes data across clinical and social sectors.

Data is fragmented across healthcare, resulting in a lack of large-scale research. Join us on September 7th for a discussion with AnalyticsIQ and Sight Outcomes Research Collaborative (SOURCE) to hear how Datavant has been working with our partners to increase data accessibility.

Life science companies have been burdened by lack of integration between internal and external data silos. Despite having access to various datasets for the same patient population, there has been no way to create a complete picture of the patient journey.

Conducting burden of illness studies and cost-effectiveness research is challenging without data that captures a patient’s complete journey from primary care to specialty clinics and inpatient care.

The benefits of leveraging real-world data (RWD) in clinical research are increasingly recognized and endorsed by regulators. As with any innovation, there is a gap between RWD availability and effectively leveraging the data, especially in the context of a randomized controlled trial (RCT).  One answer to this conundrum is to tokenize clinical trials data to enable connectivity to RWD. This webinar will focus on the operational processes to implement tokenization within a clinical trial to enable the ability to link to real–world data to answer research questions which could not previously be answered from traditional RCT designs.

For decades the best practices of clinical research involved rigidly designed, prospective randomized controlled trials (RCTs). While that remains the case in many scenarios, these kinds of trials collected data under ideal conditions and did not always reflect the routine clinical practice settings they are meant to inform. Over the last decade, as real-world data methodology advances and related regulatory guidance has matured it has allowed us to generate the evidence needed for strategy and decision making within development itself.

Conducting burden of illness studies and cost-effectiveness research is challenging without data that captures a patient’s complete journey from primary care to specialty clinics and inpatient care.